Cardiovascular Outcomes and Angiotensin Converting Enzyme Inhibitors: Beyond Blood Pressure Control: Editorial to: “Secondary Prevention of Coronary Disease with ACE Inhibition—Does Blood Pressure Reduction with Perindopril Explain the Benefits in EUROPA?” by Remme et al.

By Verma Anil   Ventura Hector  

Cardiovascular Drugs and Therapy, Vol. 23, Iss. 2, 2009-04 ,pp. : 109-111

Springer Publishing Company

Access to resources Recommend Favorite

The DD-ACE genotype and cardiovascular disease

By Butler R  

Pharmacogenomics, Vol. 1, Iss. 2, 2000-05 ,pp. : 153-167

Future Medicine

Access to resources Recommend Favorite

Circulating ACE2 in Cardiovascular and Kidney Diseases

By  

Current Medicinal Chemistry, Vol. 24, Iss. 30, 2017-10 ,pp. : 3231-3241

Bentham Science Publishers

Access to resources Recommend Favorite

Protection of Renal Function with ACE Inhibitors: Experience with Benazepril

By Aldigier J.C.  

Clinical Drug Investigation, Vol. 16, Iss. 6, 1998-12 ,pp. : 463-472

Adis International

Access to resources Recommend Favorite

Modern treatment of patients at risk: still a HOPE for ACE inhibitors?

By Angeli Fabio   Reboldi Gianpaolo   Verdecchia Paolo  

Expert Opinion on Pharmacotherapy, Vol. 12, Iss. 6, 2011-04 ,pp. : 839-843

Informa Healthcare

Access to resources Recommend Favorite